Johnson & Johnson (JNJ) Land & Improvements (2011 - 2012)
Johnson & Johnson (JNJ) posted Land & Improvements of $754.0 million for Q1 2012, up 2.17% sequentially from $738.0 million in Q1 2011, and up 2.17% YoY from $738.0 million in Q1 2011.
Johnson & Johnson (JNJ) Land & Improvements (2011 - 2012) Analysis & Trends
Johnson & Johnson has reported Land & Improvements for 2 years, with the latest figure at $754.0 million in Q1 2012.
- Quarterly Land & Improvements rose 2.17% year-over-year to $754.0 million in Q1 2012, while the trailing twelve-month figure through Jan 2012 was $754.0 million (up 2.17% YoY) and the FY2012 annual result came in at $754.0 million, up 2.17% from the prior year.
- Land & Improvements advanced to $754.0 million in Q1 2012 per JNJ's latest filing, from $738.0 million in the prior quarter.
- Over five years, Land & Improvements peaked at $754.0 million in Q1 2012 and troughed at $738.0 million in Q1 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 1, 2012 | 754.00 Mn |
| Jan 2, 2011 | 738.00 Mn |